News

RubrYc Therapeutics Winner of the 2018 Xcelerate Startup Pitch Competition

Boston, Massachusetts, September 6, 2018RubrYc Therapeutics, Inc., a biotherapeutics discovery business, announced today it was selected the winner of the 2018 Xcelerate Startup Pitch Competition held September 5, 2018, as part of Biotech Week Boston.

“I am honored to be recognized amongst such a strong field of promising biotech startups from around the world,” said Dr. Isaac Bright, CEO of RubrYc Therapeutics. “This award further validates the utility of our antibody discovery platform to identify high-value therapeutic candidates in oncology and autoimmune disease areas.”

RubrYc Therapeutics is focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. Using diverse chemical libraries developed and supplied by HealthTell, Inc., RubrYc is training algorithms that inform improved decision-making throughout drug discovery. The company collaborates with biotechnology companies in early drug discovery and develops its own pipeline of therapeutic antibodies.

“At RubrYc, we are excited to be off to a promising start and are looking forward to our fund raising over the coming year as we drive towards clinical development of our internal programs,” said Dr. Bright.

About RubrYc Therapeutics

Founded in 2017, RubrYc Therapeutics, Inc. emerged as a biotherapeutic discovery partner of immunomics leader HealthTell, Inc.  The Company has exclusive rights to HealthTell technology and combines binding information from diverse chemical library assays, with gold-standard drug discovery methods to develop biotherapeutic candidates that are optimized for clinical development. 

Contact:
Isaac J. Bright, MD
CEO

RubrYc Therapeutics, Inc.

2420 Camino Ramon

Suite 125

San Ramon, CA  94583

info@rubryc.com